Humana (NYSE:HUM) Updates FY 2024 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 16.000- for the period, compared to the consensus EPS estimate of 16.150. The company issued revenue guidance of -.

Humana Stock Performance

NYSE HUM opened at $239.85 on Thursday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a twelve month low of $213.31 and a twelve month high of $475.00. The business has a 50-day moving average price of $274.32 and a 200-day moving average price of $322.31. The firm has a market cap of $28.88 billion, a price-to-earnings ratio of 21.24, a price-to-earnings-growth ratio of 2.15 and a beta of 0.53.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The business had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. As a group, equities research analysts predict that Humana will post 16.14 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.48%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is 31.36%.

Wall Street Analyst Weigh In

HUM has been the topic of several analyst reports. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and upped their target price for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Wells Fargo & Company dropped their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Piper Sandler cut shares of Humana from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $392.00 to $274.00 in a research report on Thursday, October 3rd. Cantor Fitzgerald restated a “neutral” rating and set a $395.00 target price on shares of Humana in a research note on Tuesday, October 1st. Finally, Morgan Stanley upped their target price on shares of Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Twenty analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $300.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.